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+LGDOJR*DUFLD / *DUULGR%DUURV0 5RGULJXH]&DEH]DV0( DQG 8WULOOD03 SHUIRUPHG WKH
H[SHULPHQWVDQGFRQWULEXWHGWRWKHDFTXLVLWLRQDQGDQDO\VLVRIGDWD*DUULGR0HVD-5RGUtJXH]
1RJDOHV $ *DUFLD ) DQG &KXHFD 1 FRQWULEXWHG WR WKH WD[RQRPLF DQDO\VLV DQG GDWD
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ZLWK D SKDUPDFRORJLFDO SRWHQWLDO EH\RQG WKHLU DQWLELRWLF SURSHUWLHV 3DUWLFXODUO\PLQRF\FOLQH
DQG GR[\F\FLFOLQH KDYH VKRZQ EHQHILFLDO HIIHFWV LQ H[SHULPHQWDO FROLWLV DOWKRXJK SUR
LQIODPPDWRU\ DFWLRQV KDYH DOVR EHHQ GHVFULEHG LQ PDFURSKDJHV 7KHUHIRUH ZH DLPHG WR
FKDUDFWHULVHWKHPHFKDQLVPEHKLQGWKHLUHIIHFWLQDFXWHLQWHVWLQDOLQIODPPDWLRQ
([SHULPHQWDO$SSURDFK$FRPSDUDWLYHSKDUPDFRORJLFDOVWXG\ZDVILUVWXVHGWRHOXFLGDWH
WKH PRVW UHOHYDQW DFWLRQV RI LPPXQRPRGXODWRU\ WHWUDF\FOLQHV GR[\F\FOLQH PLQRF\FOLQH
WLJHF\FOLQH DQG RWKHU DQWLELRWLF RU LPPXQRPRGXODWRU\ GUXJV ZHUH DVVHVVHG LQ ERQHPDUURZ
GHULYHG PDFURSKDJHV DQG LQ '66LQGXFHG PRXVH FROLWLV ZKHUH GLIIHUHQW EDUULHU PDUNHUV
LQIODPPDWRU\ PHGLDWRUV PLFUR51$V 7/5V DQG WKH JXW PLFURELRWD FRPSRVLWLRQ ZHUH
HYDOXDWHG 7KHQ WKH VHTXHQWLDO LPPXQH HYHQWV WKDW PHGLDWH WKH LQWHVWLQDO DQWLLQIODPPDWRU\
HIIHFWRIPLQRF\FOLQHLQ'66FROLWLVZHUHFKDUDFWHULVHG
.H\ 5HVXOWV :H KDYH LGHQWLILHG D QRYHO LPPXQRPRGXODWRU\ DFWLYLW\ RI WHWUDF\FOLQHV
SRWHQWLDWLQJWKHLQQDWHLPPXQHUHVSRQVHDQGOHDGLQJWRDQHQKDQFHGUHVROXWLRQRILQIODPPDWLRQ
7KLVLVDOVRWKHILUVWUHSRUWGHVFULELQJ WKH LQWHVWLQDODQWLLQIODPPDWRU\HIIHFWRI WLJHF\FOLQH$
PLQRU WKHUDSHXWLF EHQHILW VHHPV WR GHULYH IURP WKHLU DQWLELRWLF SURSHUWLHV &RQYHUVHO\
LPPXQRPRGXODWRU\ WHWUDF\FOLQHV SRWHQWLDWH PDFURSKDJH F\WRNLQH UHOHDVH LQ YLWUR DQG ZKLOH
LPSURYLQJPXFRVDOUHFRYHU\LQFROLWLFPLFHWKH\XSUHJXODWH&FOPL5PL5DQG7OU
,Q SDUWLFXODU PLQRF\FOLQH LQLWLDOO\ HQKDQFHV ,/ȕ ,/ ,/ *0&6) DQG ,/ FRORQLF
SURGXFWLRQ DQGPRQRF\WH UHFUXLWPHQW WR WKH LQWHVWLQHVXEVHTXHQWO\ LQFUHDVLQJ /\&0+&,,
PDFURSKDJHV7UHJVDQGW\SHLQWHVWLQDOLPPXQHUHVSRQVHV
&RQFOXVLRQ DQG ,PSOLFDWLRQV ,PPXQRPRGXODWRU\ WHWUDF\FOLQHV SRWHQWLDWH SURWHFWLYH
LPPXQH SDWKZD\V OHDGLQJ WR PXFRVDO KHDOLQJ DQG UHVROXWLRQ UHSUHVHQWLQJ D SURPLVLQJ GUXJ
UHSRVLWLRQVWUDWHJ\IRUWKHWUHDWPHQWRILQWHVWLQDOLQIODPPDWLRQ

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WLJHF\FOLQH '(; ± GH[DPHWKDVRQH %0'0 ± %RQH PDUURZGHULYHG PDFURSKDJHV F/3 ±
FRORQLF ODPLQD SURSULD'&±'HQGULWLF&HOO0ĳ±0DFURSKDJH7K ±7 KHOSHU FHOO7UHJ ±
5HJXODWRU\7FHOO,/&±,QQDWH/\PSKRLG&HOO,%'±,QIODPPDWRU\%RZHO'LVHDVH
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,PPXQRPRGXODWRU\ DQWLELRWLFV DUH DQ LQWHUHVWLQJ WKHUDSHXWLF VWUDWHJ\ IRU LQWHVWLQDO
LQIODPPDWLRQWDUJHWLQJERWKWKHDOWHUHGPLFURELRWDDQGWKHH[DFHUEDWHGLQIODPPDWRU\UHVSRQVH
,QSDUWLFXODUPLQRF\FOLQHDQGGR[\F\FOLQHKDYHVKRZQSURPLVLQJUHVXOWVLQH[SHULPHQWDOFROLWLV
+XDQJ HW DO E *DUULGR0HVD HW DO D E  7KHVH DUH ZHOO NQRZQ
WHWUDF\FOLQHV ZLWK SURYHQ EHQHILWV LQ PDQ\ LQIODPPDWRU\ FRQGLWLRQV *DUULGR0HVD HW DO
D7KHLULQWHVWLQDODQWLLQIODPPDWRU\HIIHFWKDVEHHQPDLQO\DVVRFLDWHGZLWKWKHUHGXFWLRQ
RILQGXFLEOHQLWULFR[LGHV\QWKDVHL126DQGPDWUL[PHWDOORSURWHLQDVH003DFWLYLW\+XDQJ
HW DO E DQG GLUHFW LPPXQRPRGXODWRU\ DQG DQWLELRWLF SURSHUWLHV *DUULGR0HVD HW DO
DE+RZHYHUWKHUHOHYDQFHRIWKHVHDFWLYLWLHVWRWKHRYHUDOODQWLLQIODPPDWRU\
HIIHFW KDV QRW EHHQ VSHFLILFDO\ DVVHVVHG 2I QRWH DOWKRXJK WKHLU DFWLRQV ZLWKLQ WKH LPPXQH
V\VWHPDUHJHQHUDOO\ DQWLLQIODPPDWRU\ D FHUWDLQGHJUHHRI FRQWURYHUV\KDVEHHQREVHUYHG LQ
PRQRF\WHV DQG PDFURSKDJHV 0ĳ ZKLOH LPPXQRPRGXODWRU\ WHWUDF\FOLQHV LQKLELW WKH
LQIODPPDWRU\ DFWLYLW\ RI PLFURJOLD DQG SHULWRQHDO 0ĳV LQFUHDVHG DFWLYDWLRQ DQG F\WRNLQH
SURGXFWLRQKDVEHHQREVHUYHGLQPRQRF\WHV.ORSSHQEXUJHWDODOYHRODU0ĳV%RQMRFK
HWDODQG5$:FRORQLF0ĳFHOOOLQH'XQVWRQHWDO
,Q WKLV UHJDUG DOWKRXJK WKH LQIODPPDWRU\ UHDFWLRQPD\ FDXVHKDUPDQG WLVVXH GDPDJH D
SRZHUIXO LQWHVWLQDO PXFRVDO LPPXQH V\VWHP LV DOVR QHHGHG WR SURWHFW DQG UHVWRUH LQWHVWLQDO
KRPHRVWDVLV0RZDWDQG$JDFHZKHUH0ĳVSOD\DNH\UROH*URVVHWDO,QGHHG
XQOLNHRWKHU ORFDWLRQV WKH LQWHVWLQDO0ĳSRRO LVFRQWLQXRXVO\ UHSOHQLVKHG IURP&&5/\&KL
EORRGPRQRF\WHVZKLFKWKHQGLIIHUHQWLDWHLQWR/\&0+&,,UHVLGHQW0ĳVLQWKHVWHDG\VWDWH
,Q LQIODPPDWRU\ FRQGLWLRQV KRZHYHU WKHLU GLIIHUHQWLDWLRQ LV DUUHVWHG DQG /\&0+&,,0ĳV
DFFXPXODWH%DLQHWDOZKLFKGLVSOD\DQ0SURLQIODPPDWRU\SKHQRW\SHDQGSURGXFH
F\WRNLQHV WKDW GULYH WKH LQIODPPDWRU\ UHDFWLRQ%\ FRQWUDVW LQWHVWLQDO UHVLGHQW /\&0+&,,
0ĳV DUH WROHURJHQLF DQG GLVSOD\ DQ 0OLNH SKHQRW\SH FRQWULEXWLQJ WR PXFRVDO KHDOLQJ
UHVROXWLRQRI LQIODPPDWLRQ DQGPDLQWHQDQFH RI LQWHVWLQDO KRPHRVWDVLV 6KHUPDQ DQG.DOPDQ
3XOOHWDO+HQFHDGLIIHUHQWLDODFWLYLW\RIWHWUDF\FOLQHVRQLQWHVWLQDO0ĳVPLJKWEH
RIVSHFLDO UHOHYDQFH DQGD IXOO XQGHUVWDQGLQJRI WKHLUPHFKDQLVPV LV UHTXLUHG WR H[SDQG WKHLU
WKHUDSHXWLFDSSOLFDWLRQWRLQWHVWLQDOLQIODPPDWRU\FRQGLWLRQV
7KH SUHVHQW VWXG\ DLPV WR FKDUDFWHULVH WKH PHFKDQLVPV RI DFWLRQ RI LPPXQRPRGXODWRU\
WHWUDF\FOLQHVLQDFXWHLQWHVWLQDOLQIODPPDWLRQE\FRPSDULQJWKHLUHIIHFWVZLWKRWKHUDQWLELRWLFV
RU LPPXPRPRGXODWRU\GUXJVDQGVWXG\LQJ WKHLU LPSDFW LQWKHFRXUVHRI WKH LPPXQHUHVSRQVH
GHYHORSHGLQ'66LQGXFHGFROLWLVLQPLFH2XUUHVXOWVFRQILUPWKHUHOHYDQFHRIWKHLUGLIIHUHQWLDO
LPPXQRPRGXODWRU\ DFWLYLW\ IRU WKHLU DQWLLQIODPPDWRU\ HIIHFW DQG DOORZ HVWDEOLVKLQJ D OLQN
EHWZHHQ WKH LQLWLDO XSUHJXODWLRQ RI LQQDWH LPPXQLW\ DQG DQ LPSURYHG PXFRVDO KHDOLQJ DQG
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In vitro  107 
RAW264 murine macrophage and L929 murine fibroblast cel lines were obtained from the 108 
Cel Culture Unit of the University of Granada (Granada, Spain) and cultured in standard 109 
conditions. Bone marrowderived macrophages (BMDM) were obtained from the bonemarrow 110 
of C57BL/6J mice cultured for 6 days in DMEM supplemented with 20% FBS and 30% L929111 
supernatant containing MCSF factor. Cels were plated at 1x106 cels/ml and the drugs were 112 
added for 24h before stimulation with LPS (100 ng/ml for RAW cels or 10 ng/ml for BMDM) 113 
for either 3h for RNA isolation, or 24h for cytokine determination by ELISA (PeproTech EC 114 
Ltd, London, UK) or nitrite determination by Griess assay (Green et al., 1982). Briefly, for 115 
nitrite determination, 100µl of Griess reagent (0.1 % N(1naphthy) ethylenediamine solution 116 
and 1% sulphanilamide in 5% (v/v) phosphoric acid solution, mixed in a proportion 1:1) was 117 
added to 100µl of cel supernatant and incubated for 10 minutes. The concentration of the 118 
product of the reaction, a coloured azolic compound, can be determined by photometric 119 
measurement of the absorbance at 550 nm. Cel viability of tested conditions was measured by 120 
the MTSbased assay (Promega, Madison, WI, USA).  121 
In vivo  122 
Al animal studies were carried out in accordance with the ‘Guide for the Care and Use of 123 
Laboratory Animals’ as promulgated by the National Institute of Health. Animal studies are 124 
reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and 125 
Liley, 2015). Male C57BL/6J mice (68 weeks, 25 g) were obtained from Janvier (St Berthevin 126 
Cedex, France) and kept in specific pathogen–free facilities at University of Granada Biological 127 
Services Unit at 23 ± 1°C, with a relative humidity of 50–70% andon a regular 12 h dark/light 128 
cycle. Mice were housed in Makrolom cages (Ehret, Emmerdingen, Germany), with a maximum 129 
of 8 mice per cage, with dust‐free laboratory bedding and enrichment. They were fed standard 130 
chow diet (Panlab A04, Panlab, Barcelona, Spain) and provided drinking water ad libitum. 131 
To investigate the mechanism behind the beneficial activity previously reported for 132 
tetracyclines (GarridoMesa et al., 2011a, 2011b, 2015) and, in particular, to characterize their 133 
impact on the pathways involved in the initiation and resolution of acute intestinal 134 
inflammation, we focused on the experimental model of colitis triggered by DSSinduced 135 
mucosal injury, the most widely used model of acute colitis (Wirtz et al., 2007). A curative 136 
treatment protocol was used considering the lack of preventive effect observed in previous 137 
studies (GarridoMesa et al., 2011a) and taking in consideration the limitations on antibiotic 138 
usage in the clinical practise. Colitis was induced by adding DSS (3% w/v) (3650KDa, MP 139 
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WKHVWXG\ 'LVHDVH HYROXWLRQ ZDVPRQLWRUHG E\ D GDLO\ GHWHUPLQDWLRQ RI WKH GLVHDVH DFWLYLW\
LQGH['$,FDOFXODWHGDVGHVFULEHGLQWDEOH0LFHZHUHDQHVWKHWLVHGZLWKNHWDPLQH[\OD]LQH
DQGPJNJ UHVSHFWLYHO\ IRUEORRGFROOHFWLRQE\ FDUGLDFSXQFWXUHZKHQ UHTXLUHGDQG
VDFULILHGE\FHUYLFDOGLVORFDWLRQDQGWKHZKROHFRORQOHQJWKZDVUHVHFWHG6WRROVZHUHFROOHFWHG
DVHSWLFDOO\ IRU S\URVHTXHQFLQJ 7KH FRORQLF WLVVXH ZDV ZDVKHG LQ 3%6 DQG VDPSOHV ZHUH
FROOHFWHGIRUVXEVHTXHQWKLVWRORJLFDOELRFKHPLFDODQGLPPXQRORJLFDOHYDOXDWLRQV
+LVWRORJ\
5HSUHVHQWDWLYH FRORQLFVSHFLPHQVZHUH WDNHQ DW FP IURP WKH GLVWDO UHJLRQ IL[HG LQ 
SDUDIRUPDOGHK\GHDQGHPEHGGHGLQSDUDIILQ+LVWRFKHPLFDOVWDLQLQJRIPXFLQVZDVSHUIRUPHG
E\ LQFXEDWLRQ RI  P UHK\GUDWDWHG VHFWLRQV LQ $OFLDQ %OXH  LQ $FHWLF DFLG  IRU 
PLQXWHV SULRU WR FRQYHQWLRQDO KDHPDWR[\OLQ DQG HRVLQVWDLQLQJ &RORQLFPLFURVFRSLF GDPDJH
ZDV HYDOXDWHG E\ D SDWKRORJLVW REVHUYHU EOLQGHG WR WKH H[SHULPHQWDO JURXSV DFFRUGLQJ WR WKH
FULWHULDGHVFULEHGLQWDEOH
&RORQLFH[SODQWFXOWXUHDQGF\WRNLQHGHWHUPLQDWLRQE\(/,6$
:KROH WKLFN FRORQLF SXQFK ELRSVLHV  SHU VSHFLPHQ 0LOWH[ <RUN 3$ 86$ ZHUH




5HSUHVHQWDWLYH FRORQLF VDPSOHV ZHUH WDNHQ IRU 51$ H[WUDFWLRQ DQG JHQH H[SUHVVLRQ
VWXGLHV,Q WKHFRPSDUDWLYHSKDUPDFRORJLFDOVWXG\RQ'66FROLWLVZKHUHERWKPLFUR51$VDQG
P51$V ZHUH HYDOXDWHG WRWDO 51$ ZDV LVRODWHG ZLWK PL51HDV\ PLQL .LW 4LDJHQ +LOGHQ
*HUPDQ\DQGQJRI51$ZDVUHYHUVHWUDQVFULEHGXVLQJWKHPL6FULSW,,57NLWIURP4LDJHQ





.$3$ 6<%5 )$67 T3&5 0DVWHU 0L[ .DSD%LRV\VWHPV ,QF :LOPLQJWRQ 0$ 86$
'HWHFWLRQZDVSHUIRUPHGRQRSWLFDOJUDGHZHOOSODWHVLQDQ(FR705HDO7LPH3&56\VWHP
,OOXPLQD&$86$7KHVPDOO QXFOHRODU51$&'ER[ 6125' DQG*$3'+ZHUH
PHDVXUHG WR QRUPDOLVH PLFUR51$ DQG P51$ H[SUHVVLRQ ǻ&W UHVSHFWLYHO\ )ROG LQFUHDVH
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YDOXHV IRUJHQHH[SUHVVLRQDQDO\VLVZHUH FDOFXODWHGXVLQJQRUPDOLVHGH[SUHVVLRQ OHYHOVǻ&W
UHIHUUHG WR WKHPHDQRI1&FRQWURO JURXS )ROG ,QFUHDVH ǻ&Wǻ&W1&6125'PL51$
DQG UHYHUVH XQLYHUVDO SULPHU IRU PL51$ 4LDJHQ DQG ,/ 3ULPHU'HVLJQ ZHUH VRXUFHG
FRPPHUFLDOO\7KHUHPDLQLQJVSHFLILFSULPHUVHTXHQFHV6LJPDDUHGHWDLOHGLQWDEOH
%DFWHULDO'1$S\URVHTXHQFLQJDQGDQDO\VLV
'1$ IURP IDHFDO FRQWHQW ZDV LVRODWHG XVLQJ SKHQROFKORURIRUP H[WUDFWLRQ DQG HWKDQRO
SXULILFDWLRQ 6DPEURRN DQG 5XVVHOO  6 U51$ JHQHVHTXHQFH UHFRYHU\ DQG LQWHJULW\
ZDV3&5DPSOLILHGXVLQJSULPHUVWDUJHWLQJUHJLRQVIODQNLQJWKHYDULDEOHUHJLRQVWKURXJKRI
WKH EDFWHULDO 6 U51$ JHQH 9 JHO SXULILHG DQG DQDO\]HG XVLQJ WKH 5RFKH *6
7LWDQLXPWHFKQRORJ\5RFKH'LDJQRVWLFV%UDQIRUG&786$7KHDPSOLILFDWLRQRIDES
VHTXHQFH LQ WKHYDULDEOHUHJLRQ99RI WKH6U51$JHQHZDVSHUIRUPHGXVLQJEDUFRGHG
SULPHUV 3&5 ZDV SHUIRUPHG LQ D WRWDO YROXPH RI  ȝ/ IRU HDFK VDPSOH FRQWDLQLQJ WKH
XQLYHUVDO)DQG%LI6) IRUZDUGSULPHUV ȝPRO/ DW D UDWLR UHVSHFWLYHO\ DQG WKH
EDUFRGHG XQLYHUVDO UHYHUVH SULPHU 5  ȝPRO/ LQ DGGLWLRQ WR G173PL[ PPRO/
)DVW6WDUWîEXIIHUZLWKPPRO/RI0J&O)DVW6WDUW+L)LSRO\PHUDVH8LQP/DQG
ȝ/ RI JHQRPLF '1$ 7KH G173 PL[ )DVW6WDUW î EXIIHU ZLWK0J&O DQG )DVW6WDUW +L)L
SRO\PHUDVH ZHUH LQFOXGHG LQ D )DVW6WDUW +LJK )LGHOLW\ 3&5 6\VWHP G173 3DFN 5RFKH
$SSOLHG6FLHQFH3HQ]EHUJ*HUPDQ\7KH3&5FRQGLWLRQVZHUHDVIROORZV&IRUPLQ
F\FOHVRI&IRUV&IRUVDQG&IRUPLQDQGILQDOVWHSDW&$IWHU
3&5 DPSOLFRQV ZHUH IXUWKHU SXULILHG XVLQJ $03XUH ;3 EHDGV %HFNPDQ &RXOWHU ,QF
,QGLDQDSROLV ,1 86$ WR UHPRYH VPDOOHU IUDJPHQWV '1$ FRQFHQWUDWLRQ DQG TXDOLW\ ZHUH
PHDVXUHG XVLQJ D 4XDQWL7 3LFR*UHHQ GV'1$ $VVD\ .LW 7KHUPR )LVKHU 6FLHQWLILF
:DOWKDP0$86$)LQDOO\WKH3&5DPSOLFRQVZHUHFRPELQHGLQHTXLPRODUUDWLRVWRFUHDWH
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&HOO IURPWKHFRORQLFODPLQDSURSULD F/3ZHUH LVRODWHGDVGHVFULEHG6FRWWHWDO
XVLQJDGLJHVWLRQPHGLDFRPSRVHGRI+%66ZLWKRXW0JRU&DRI)%6DQGPJPO
FROODJHQDVH96LJPDPJPOFROODJHQDVH'ȝJPO'1DVH,DQGPJPOGLVSDVH,,DOO
5RFKH %ORRG ȝOZDV FROOHFWHG DQG UHG EORRG O\VLVZDVSHUIRUPHG DV QHHGHG 6XUIDFH
VWDLQLQJDQWLERGLHVZHUHDGGHGWRWKHFHOOVXVSHQVLRQWRJHWKHUZLWKDYLDELOLW\VWDLQ,QYLWURJHQ
DQG )F5 EORFNLQJ UHDJHQW 0LOWHQ\L IRU  PLQXWHV DW & )RU LQWUDFHOOXODU F\WRNLQH
H[SUHVVLRQFHOOVZHUHSUHYLRXVO\VWLPXODWHG30$QJPODQGLRQRP\FLQȝJPO6LJPD
$OGULFKLQWKHSUHVHQFHRI*ROJL3OXJ70H%LRVFLHQFHIRUKRXUVDW&)RULQWUDFHOOXODU
VWDLQLQJ RI F\WRNLQHV DQG WUDQVFULSWLRQ IDFWRUV FHOOV ZHUH IL[HG LQ )L[DWLRQ3HUPHDELOL]DWLRQ
EXIIHU )R[3 VWDLQLQJ NLW H%LRVFLHQFH DQG DQWLERGLHV ZHUH DGGHG IROORZLQJ WKH
PDQXIDFWXUHU¶V LQVWUXFWLRQV$QWLERGLHVZHUH IURP0LOWHQ\L XQOHVVRWKHUZLVHVWDWHG ĮPRXVH
&')ĮKXPDQĮPRXVH&'E0ĮPRXVH/\*5($ĮPRXVH
6LJOHF) 5($ ĮPRXVH 0+&,, 0 ĮPRXVH /\& ** ĮPRXVH
&'(ĮPRXVH&'F1ĮPRXVH)5($ĮPRXVH%5$%
%' %LRVFLHQFH ĮPRXVH &' $ ĮPRXVH &'  ĮPRXVH &' 50 %'
%LRVFLHQFHĮPRXVH,/%9''ĮPRXVH,)1J;0*%'3KDUPLJHQĮPRXVH
,/$ H%LR% H%LRVFLHQFH ĮPRXVH )R[3 )-.V H%LRVFLHQFH 6DPSOHV ZHUH
DFTXLUHGXVLQJD)$&69HUVHRU)$&6&DQWR,,F\WRPHWHUV%HFWRQ'LFNLQVRQ86$DQG









SDUDPHWULF GDWD ZHUH DQDO\]HG XVLQJ WKH0DQQ:KLWQH\ 8WHVW $OO VWDWLVWLFDO DQDO\VHV ZHUH
FDUULHG RXW ZLWK WKH 6WDWJUDSKLFV  VRIWZDUH SDFNDJH 676& 0DU\ODQG ZLWK VWDWLVWLFDO
VLJQLILFDQFHVHWDW3
0DWHULDOV
$OO FKHPLFDOVZHUH REWDLQHG IURP6LJPD 0DGULG 6SDLQ XQOHVVRWKHUZLVHVWDWHG'UXJ
GRVHVXVHGLQPLFHZHUHHTXLYDOHQWWRWKHWKHUDSHXWLFGRVHLQKXPDQV 
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7KH LPPXQRPRGXODWRU\DFWLYLW\RIGLIIHUHQW WHWUDF\FOLQHVZDV LQLWLDOO\FRPSDUHG LQ/36
DFWLYDWHG 5$: PDFURSKDJHV 7LJHF\FOLQH 7*& ZDV WKH PRVW SRWHQW LQKLELWRU RI 12
SURGXFWLRQIROORZHGE\PLQRF\FOLQH01&DQGGR[\F\FOLQH';&DOWKRXJKWKHDFWLYLW\RI
GH[DPHWKDVRQH '(; ZDVVWURQJHU 2Q WKH RWKHU KDQG QRVLJQLILFDQW LQKLELWRU\ HIIHFW ZDV
REVHUYHG IRU WHWUDF\FOLQH 77& RU ULID[LPLQ 5); DW WKH YLDEOH FRQFHQWUDWLRQV DVVD\HG
)LJ$ 7KHQ WKH LPPXQRPRGXODWRU\ WHWUDF\FOLQHV ZHUH HYDOXDWHG LQ ERQHPDUURZ GHULYHG





,PPXQRPRGXODWRU\ WHWUDF\FOLQHV DPHOLRUDWH '66FROLWLV VKRZLQJ D EHWWHU SURILOH
WKDQULID[LPLQWHWUDF\FOLQHDQGGH[DPHWKDVRQH
,QLWLDOO\WKHFRPSRXQGVZHUHDVVD\HGIROORZLQJDIDWDOFROLWLVSURWRFROLQPLFHLQGXFHGE\
DGPLQLVWHULQJ '66 IRU  GD\V 7KHQ PLFH ZHUH WUHDWHG IRU  GD\V ZLWK   5); 
PJNJGD\ D QRQDEVRUEDEOH DQWLELRWLF  77&  PJNJGD\ LQFOXGHG DV UHIHUHQFH RI
WHWUDF\FOLQHV¶ DQWLELRWLF DFWLYLW\  LPPXQRPRGXODWRU\ WHWUDF\FOLQHV';& PJNJGD\




YDOXHV DIWHU WKH WKLUG GD\ RI WUHDWPHQW LQ FRQWUDVW ZLWK WKH LQLWLDO UHGXFWLRQ REVHUYHG 77&
WUHDWHGPLFHVKRZHGDVOLJKWLPSURYHPHQWDOWKRXJKQRVWDWLVWLFDOGLIIHUHQFHVZHUHREVHUYHGLQ
FRPSDULVRQZLWK'66FRQWURODQG5);GLGQRWVKRZDQ\EHQHILFLDOHIIHFW0RUHRYHUDKLJK
PRUWDOLW\ UDWH ZDV H[SHULHQFHG IURP GD\  LQ FROLWLF PLFH ZLWK RQO\  RI WKH DQLPDOV
VXUYLYLQJ XQWLO WKH HQG RI WKH VWXG\ DQG RQO\ WKRVH FROLWLF JURXSV WUHDWHG ZLWK
LPPXQRPRGXODWRU\WHWUDF\FOLQHVVKRZHGDVLJQLILFDQWO\LQFUHDVHGVXUYLYDO)LJ%
6XEVHTXHQWO\ WKHHIIHFWRI WKHVHGUXJVZDV WHVWHG LQD OHVVDJJUHVVLYHFROLWLVSURWRFRO LQ
ZKLFK'66 LQWDNH ZDVPDLQWDLQHG IRUGD\V IROORZHGE\ DGD\SHULRGRI WUHDWPHQW
7KH '$, HYROXWLRQ IROORZHG D VLPLODU SDWWHUQ RQO\ WKH LPPXQRPRGXODWRU\ WHWUDF\FOLQHV
VLJQLILFDQWO\ DPHOLRUDWHG '$, YDOXHV )LJ$ +LVWRORJLFDO DQDO\VLV VKRZHG WKDW '66FROLWLV
PDLQO\DIIHFWHGWKHPXFRVDZLWKHSLWKHOLDOXOFHUDWLRQLQPRUHWKDQRIWKHFRORQLFVXUIDFH
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0DMRU KLVWRORJLFDO DOWHUDWLRQV DIIHFWHG WKH FU\SW VWUXFWXUH ZLWK KLJK PLWRWLF DFWLYLW\ PXFLQ
GHSOHWLRQ LQ JREOHW FHOOV SUHVHQFH RI RHGHPD DQG LQWHQVH LQIODPPDWRU\ FHOO LQILOWUDWLRQ
,PPXQRPRGXODWRU\ WHWUDF\FOLQHV VLJQLILFDQWO\ UHGXFHG WKH PLFURVFRSLF GDPDJH VFRUH
SUHVHUYLQJWKHPXFRVDOOD\HUDQGUHVWRULQJWKHSUHVHQFHRIPXFXVILOOHGJREOHWFHOOV+RZHYHU
QR KLVWRORJLFDO LPSURYHPHQW ZDV REVHUYHG LQ FROLWLF PLFH WUHDWHG ZLWK 5); 77& RU '(;
)LJ%& 7KHPXFLQ GHSOHWLRQ REVHUYHG LQ '66FRQWURO PLFH ZDV DVVRFLDWHGZLWK UHGXFHG
H[SUHVVLRQRI0XF0XFDQG0XFDQGRIWKHHSLWKHOLDOEDUULHULQWHJULW\PDNHUV=RDQG
2FFOXGLQ ,PSRUWDQWO\ WKHLU H[SUHVVLRQ ZDV LPSURYHG LQ DQLPDOV WUHDWHG ZLWK
LPPXQRPRGXODWRU\ WHWUDF\FOLQHV ZKLFK DOVR VKRZHG DQ XSUHJXODWLRQ RI 7II H[SUHVVLRQ ,Q
FRQVWUDVW5);DQG'(;WUHDWPHQWVGLGQRWUHVWRUHWKHH[SUHVVLRQRIWKHVHSURWHFWLYHPDUNHUV
ZKLFKDSSHDUHGHYHQIXUWKHUUHGXFHGLQ5);WUHDWHGPLFH)LJ'
:KHQGLIIHUHQW LQIODPPDWRU\PHGLDWRUVZHUH FRQVLGHUHG'66LQGXFHGFROLWLVZDV OLQNHG
WR DQ LQFUHDVHGH[SUHVVLRQRI7QIĮ ,Oȕ ,O0PS&FODQG&[FO )LJ7KH WUHDWPHQW
ZLWK LPPXQRPRGXODWRU\ WHWUDF\FOLQHV VLJQLILFDQWO\ UHGXFHG ,Oȕ ,O 0PS DQG &[FO
H[SUHVVLRQZKLOH WKH RWKHU GUXJVVKRZHGQR HIIHFW 6WULNLQJO\&FO H[SUHVVLRQZDVVWURQJO\
SRWHQWLDWHGLQPLFHWUHDWHGZLWK';&01&DQG7*&DQGWRDOHVVHUH[WHQWZLWK77&5HFHQW
VWXGLHV KDYH KLJKOLJKWHG WKH UROH RI PLFUR51$V LQ WKH UHJXODWLRQ RI LQWHVWLQDO LQIODPPDWLRQ
%LWRQHWDO3HNRZDQG.ZRQ,QRXUVWXG\'66FROLWLVLQGXFHGDVLJQLILFDQWXS
UHJXODWLRQRIPL5PL5DQGPL5)LJ7KHWHWUDF\FOLQHVDQG'(;UHGXFHGPL5
 DQG PL5 H[SUHVVLRQ ZKLFK KDYH EHHQ DVVRFLDWHG ZLWK 7 KHOSHU FHOO DQG KXPRUDO
UHVSRQVHV0RQWLFHOOLHWDODQGWKH1)ț%SDWKZD\7LOLHWDOUHVSHFWLYHO\7KH
DGPLQLVWUDWLRQ RI WHWUDF\FOLQHV WR FROLWLFPLFH UHVXOWHG LQ DQ XSUHJXODWLRQ RIPL5ZKLFK
DOLJQVZLWKLQFUHDVHG7IIH[SUHVVLRQERWKUHODWHGWRJREOHWFHOOIXQFWLRQ%LWRQHWDO
0L5 SUHIHUHQWLDOO\ H[SUHVVHG LQ LPPXQH FHOOV .UDPHU HW DO  ZDV WKH PRVW
XSUHJXODWHGPL51$XSRQFROLWLVLQGXFWLRQDQGVWULNLQJO\LWVH[SUHVVLRQZDVIXUWKHULQFUHDVHG
LQPLFHWUHDWHGZLWKWKHLPPXQRPRGXODWRU\WHWUDF\FOLQHVDQHIIHFWVLPLODUWRWKHRQHREVHUYHG
LQ &FO H[SUHVVLRQ ,Q DGGLWLRQ WKH FRORQLF LQIODPPDWRU\ SURFHVV KDV EHHQ DVVRFLDWHG ZLWK
FKDQJHV LQ PLFURELDO VHQVLQJ WKURXJK 7/5V )UDQFKLPRQW HW DO  :H REVHUYHG D




:KHQ FRQVLGHULQJ WKH LPSDFW RQ FRORQLF PLFURELRWD FRPSRVLWLRQ ZKLOH QR VWDWLVWLFDO
GLIIHUHQFHVZHUH REVHUYHG LQ ĮGLYHUVLW\ DW WKLV WLPH SRLQW WDEOH  LQQHU WD[RQRPLF JURXSV
VKRZHG D KLJKHU GHJUHH RI YDULDWLRQ DV LW KDV EHHQ GHVFULEHG DW HDUO\ VWDJHV RI LQWHVWLQDO
LQIODPPDWLRQ 6FKZDE HW DO  %DFWHURLGHWHV DEXQGDQFH ZDV UHGXFHG LQ '66FRQWURO
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FROLWLFPLFH FRXQWHUDFWHG WKHVH FKDQJHVZKLOH'(; WUHDWPHQWVKRZHGPLQRU HIIHFW )LJ$
2UGHU OHYHO KHDWPDS DQG FOXVWHULQJ DQDO\VLV LOXVWUDWHV WKHVH UHVXOWV EDVHG RQ WKHLU GLIIHUHQW
FRPSRVLWLRQPDLQO\RI%DFWHURLGDOHV'66DQG'(;DQLPDOVFOXVWHULQDVHSDUDWHGEUDQFKIURP
DQWLELRWLFWUHDWHG DQG KHDOWK\ PLFH )LJ% +RZHYHU DQDO\VLV DW ORZHU WD[RQRPLF OHYHOV
UHYHDOHG WKDW DQWLELRWLF WUHDWPHQW VKRZHG D GLYHUJHQW LPSDFW 3&$ DW JHQXV OHYHO GHOLPLWDWH
WKUHH GLIIHUHQW FOXVWHUV ZLWK GLIIHUHQW PLFURELRWD FRPSRVLWLRQ 1& FRQWURO '66 DQG '(;
WUHDWHGFROLWLFPLFHDQGDQWLELRWLFWUHDWHGJURXSV1RPDMRUGLIIHUHQFHVZHUHREVHUYHGDPRQJ
WKHDQWLELRWLFVZKLFKH[HUWHGDKLJKHULPSDFWLQWKHPLFURELRWDFRPSRVLWLRQGLVWULEXWHGDORQJ
3& D[LV ZKLFK H[SODLQV  RI WKH YDULDQFH WKDQ WKH FROLWLV LWVHOI VHSDUDWHG LQ 3&
DFFRXQWLQJ IRU  RI YDULDELOLW\ )LJ& $V DQ H[DPSOH RI WKLV GLYHUJHQFH FROLWLV
DVVRFLDWHG UHGXFWLRQ RI %DFWHURLGHWHV LQFOXGHG IDPLOLHV VXFK DV 3RUSK\URPRQDFHDH DQG
3UHYRWHOODFHDHZKLOHWKHLPSDFWRIDQWLELRWLFVZDVJUHDWHUZLWKLQ%DFWHURLGDFHDHPDLQO\GXH
WR DQ LQFUHDVH LQ WKH DEXQGDQFH RI%DFWHURLGHV DFLGLIDFLHQV:LWKLQ WKH 3K\OXP)LUPLFXWHV
DQWLELRWLFVFRXQWHUDFWHGWKHLQFUHDVHLQ%DFLOOLFODVVREVHUYHGLQFROLWLVDQGZLWKLQLWRQO\01&
DQG7*&VLJQLILFDQWO\UHGXFHG/DFWREDFLOODFHDHIDPLO\)LJ$
0LQRF\FOLQH SRWHQWLDWHV WKH HDUO\ LQIODPPDWRU\ UHVSRQVH DQG SURPRWHV PXFRVDO
KHDOLQJDQGUHVROXWLRQLQ'66FROLWLV
&RQVLGHULQJ WKHLUHIIHFWVRQ0ĳV LQYLWUR DQG WKHGLIIHUHQWLDO LPPXQRPRGXODWRU\DFWLYLW\
REVHUYHGIRUWHWUDF\FOLQHVLQYLYRSDUWLFXODUO\WKHXSUHJXODWLRQRI&FODQGPL5DVVRFLDWHG
ZLWKWKHJHQHUDWLRQRIW\SHLPPXQLW\*XHWDO%HO]ZHDQDO\VHGWKHHIIHFWVRI
01&RQ WKH LQLWLDO LPPXQRORJLFDOHYHQWVRI WKH LQWHVWLQDO LQIODPPDWRU\SURFHVV2QFHFROLWLV
ZDVHVWDEOLVKHGDIWHUGD\VRI'66WUHDWPHQWPLFHZHUHWUHDWHGZLWK01&PJNJIRU
 GD\V DW WKLV WLPH SRLQW WKH FRORQLF LQIODPPDWRU\VWDWXVZDV HYDOXDWHG ELRFKHPLFDOO\ DQG
FLUFXODWLQJDQGFRORQLF/DPLQD3URSULDF/3 LPPXQHSRSXODWLRQVZHUH LVRODWHGDQGDQDO\VHG
E\IORZF\WRPHWU\1RPDMRUGLIIHUHQFHVZHUHREVHUYHG LQEORRG OHXNRF\WHVEHWZHHQ1&DQG








LQ '66FRQWURO PLFH ZDV IXUWKHU LQFUHDVHG LQ 01&WUHDWHG PLFH $GGLWLRQDOO\ RWKHU
LQIODPPDWRU\PHGLDWRUVZHUHDOVRXSUHJXODWHG LQWKH01&WUHDWHGJURXS LQFRPSDULVRQZLWK
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'66FRQWUROVVXFK DV ,O ,O &FO DQG&FO H[SUHVVLRQ DQG ,/*0&6) DQG ,/
FRQFHQWUDWLRQ LQ WKH VXSHUQDWDQW RI FRORQLF H[SODQWV IURP01&WUHDWHG PLFH ZHUH VLPLODUO\
LQFUHDVHG)LJ&'
7KHQ WKH HIIHFWV RI 01& ZHUH FKDUDFWHULVHG DIWHU  GD\V RI WUHDWPHQW ZKHQ 01&
LQWHVWLQDO DQWLLQIODPPDWRU\ DFWLYLW\ZDV IXOO\ GLVSOD\HGZLWK ORZHU'$, YDOXHV DQGPDUNHG
KLVWRORJLFDO LPSURYHPHQW )LJ$% $W WKLV WLPH SRLQW WKH V\VWHPLF LPPXQH UHVSRQVH LQ
FROLWLF PLFH ZDV FKDUDFWHULVHG E\ DQ LQFUHDVH LQ FLUFXODWLQJ P\HORLG FHOOV SDUWLFXODUO\
QHXWURSKLOV,QWHUHVWLQJO\01&WUHDWPHQWVLJQLILFDQWO\UHGXFHGWKHQHXWURSKLOLDZKLOHP\HORLG
PRQRF\WLFFHOOVDQGHRVLQRSKLOVZHUHVWLOOHOHYDWHGLQWKLVJURXS)LJ&'
)ORZ F\WRPHWU\ DQDO\VLV RI F/3 OHXNRF\WHV VKRZHG WKDW WKH &' FHOO QXPEHU ZDV
VOLJKWO\ KLJKHU LQ01&WUHDWHG JURXS WKDQ LQ'66FRQWUROPDLQO\ DVVRFLDWHGZLWK LQFUHDVHG
SUHVHQFH RI &'E P\HORLG FHOOV )LJ$% $PRQJ WKHP 01& WUHDWPHQW VLJQLILFDQWO\
UHGXFHGQHXWURSKLOVZKLOHLWLQFUHDVHGWKHQXPEHUVRIHRVLQRSKLOVDQGPRQRF\WLFP\HORLGFHOOV
)LJ&'7KHVHILQGLQJVDOLJQUHVSHFWLYHO\ZLWKLQFUHDVHG&FODQG&FOWUDQVFULSWVGHWHFWHG
LQ WKH FRORQ RI PLFH DIWHU  GD\V RI 01& WUHDWPHQW )LJ& 7KH SKHQRW\SH RI F/30ĳV
&'E/\*66&OR) DQG '&V 66&OR)&'FKL0+& ZDV IXUWKHU FKDUDFWHULVHG
FRQILUPLQJWKDW01&WUHDWHGPLFHSUHVHQWHGDQLQFUHDVHGQXPEHURI0ĳVDQG'&VLQWKHF/3
)LJ(DQG+7KHPRQRF\WH0ĳGLIIHUHQWLDWLRQZDWHUIDOO)LJ)LOOXVWUDWHVWKHDFFXPXODWLRQ
RI WKH LQLWLDO/\&KL SRSXODWLRQ LQ WKH LQIODPHG LQWHVWLQH'HVSLWH WKDW01&WUHDWHGPLFHKDG
KLJKHUQXPEHUVRI0ĳVLQWKHF/3WKDQWKH'66FRQWUROVERWKJURXSVKDGVLPLODUQXPEHUVRI
LQIODPPDWRU\ 0ĳV ZKLOH WKH LQWHUPHGLDWH DQG WLVVXHUHVLGHQW 0ĳ SRSXODWLRQV ZHUH
VLJQLILFDQWO\ LQFUHDVHG LQ 01&WUHDWHG PLFH )LJ* $PRQJ LQWHVWLQDO '&V '66FROLWLV
LQGXFHG WKHLUSRODUL]DWLRQ WRZDUGV WKH&'E&'SKHQRW\SH )LJ, WKHPDLQPLJUDWRU\
SRSXODWLRQ 01& WUHDWPHQW UHVXOWHG LQ DQ LQFUHDVH RI WKH WRWDO QXPEHU RI '&V LQ WKH F/3
ZLWKRXWDOWHULQJWKHSRODUL]DWLRQRI'&V)LJ+:KHQFRQVLGHULQJWKHO\PSKRLGFRPSDUWPHQW
D VWURQJ % FHOO LQILOWUDWH ZDV REVHUYHG LQ FROLWLF PLFH ZKLFK ZDV QRW PRGLILHG E\ 01&
WUHDWPHQW:LWKLQWKH&'O\PSKRF\WHFRPSDUWPHQWQRGLIIHUHQFHVZHUHREVHUYHG LQ&'7
FHOOVQXPEHUVDPRQJVWWKHGLIIHUHQWJURXSV)LJ$+RZHYHUWKHQXPEHURIF/3&'7FHOOV
DQG SDUWLFXODUO\ RI ,/ DQG)R[S&'7 KHOSHU FHOOVZDV KLJKHU LQ FROLWLFPLFH WKDQ LQ
KHDOWK\ FRQWUROV DQG WKHVH DSSHDUHG IXUWKHU LQFUHDVHG LQ 01&WUHDWHG PLFH )LJ$ $V
REVHUYHG EHIRUH WKH SURGXFWLRQ RI ,/ D 7KUHODWHG F\WRNLQH ZDV LQFUHDVHG LQ FRORQLF
H[SODQWVIURPFROLWLFDQLPDOVEHLQJHYHQKLJKHULQ01&WUHDWHGFROLWLFPLFH)LJ%+LJKHU
QXPEHUV RI ,/SURGXFLQJ 7K O\PSKRF\WHV ZHUH IRXQG LQ WKH F/3 RI 01&WUHDWHG PLFH
ZKLOH QR GLIIHUHQFHV ZHUH REVHUYHG DPRQJVW 1& DQG '66 JURXSV )LJ$ $GGLWLRQDOO\
FRORQLF H[SODQWV IURP 01&WUHDWHG PLFH SURGXFHG KLJKHU ,/ WKDQ 1& DQG '66 JURXSV
)LJ%,QWHUHVWLQJO\LQFUHDVHGQXPEHUVDQGSHUFHQWDJHVRI,/,/$DQG,/$)R[3
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RI01&WUHDWHGPLFHZHHYDOXDWHG WKH H[SUHVVLRQRI$OR[ZKLFKHQFRGHVIRU WKHHQ]\PH
OLSR[\JHQDVH LQYROYHG LQ WKH V\QWKHVLV RI SURUHVROYLQJ OLSLG PHGLDWRUV :DQJ DQG
&ROJDQ  ,QWHUHVWLQJO\$OR[ H[SUHVVLRQZDVVLJQLILFDQWO\ XSUHJXODWHG LQ WKH FRORQLF
WLVVXHRIWKH01&WUHDWHGJURXSFRPSDUHGWRWKH'66FRQWURO)LJ& 
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PLQRF\FOLQH DQG GR[\F\FOLQH LQ SUHFOLQLFDOPRGHOV RI LQWHVWLQDO LQIODPPDWLRQ +XDQJ HW DO
E D*DUULGR0HVD HW DO D E ZHDLPHG WR IXUWKHU LQYHVWLJDWH WKH
SRWHQWLDO RI WKLV LQWHUHVWLQJ WKHUDSHXWLF IDPLO\ RI LPPXQRPRGXODWRU\ DQWLELRWLFV :H KDYH
LGHQWLILHG DQ LPSRUWDQW OLQN EHWZHHQ WKH HIIHFW RI LPPXQRPRGXODWRU\ WHWUDF\FOLQHV DQG WKH
DFWLYDWLRQRIVSHFLILF LQIODPPDWRU\SDWKZD\VOHDGLQJWRWKHUHVROXWLRQRILQIODPPDWLRQZKLFK
VXSSRUWVWKHSRWHQWLDORIWKHVHPROHFXOHVDVRUJDQSURWHFWLYHDJHQWV*ULIILQHWDO
0RUHRYHU WKLV VWXG\ DOVR FRQVWLWXWHV WKH ILUVW GHVFULSWLRQ RI WKH LQWHVWLQDO DQWLLQIODPPDWRU\
DFWLYLW\ RI WLJHF\FOLQH2XU UHVXOWVVXJJHVW WKDW WKH DQWLELRWLF DFWLYLW\ SHUVH GRHV QRW H[HUW D
VLJQLILFDQWFRQWULEXWLRQWRWKHDQWLLQIODPPDWRU\HIIHFWRIWHWUDF\FOLQHVLQWKLVPRGHORIFROLWLV
VLQFH DOO DQWLELRWLFVKDGDVLPLODU LPSDFW LQPLFURELRWD EXW QR EHQHILFLDO HIIHFWZDVREVHUYHG
ZLWK 5); RU 77& +RZHYHU LPPXQRPRGXODWRU\ WHWUDF\FOLQHV KDYH GHPRQVWUDWHG D SURPSW
HIIHFW GULYLQJ D VWURQJ LPSURYHPHQW RI WKH HSLWKHOLDO EDUULHU LQWHJULW\ DQG UHGXFLQJ FROLWLV
DVVRFLDWHGPRUWDOLW\UDWH7KHVHILQGLQJVVXSSRUWWKHLGHDWKDWWKHDFWLYDWLRQRILQQDWHLPPXQH
SURWHFWLRQ DV RSSRVHG WR WKH LPPXQH LQKLELWLRQ FDXVHG E\ GH[DPHWKDVRQH FRXOG LQ IDFW
FRQVWLWXWHDQDGYDQWDJHLQWKHWUHDWPHQWRILQWHVWLQDOLQIODPPDWLRQ3DUWLFXODUO\FRQVLGHULQJWKH
HIIHFWVGLVSOD\HGE\WHWUDF\FOLQHVRQPDFURSKDJHVLQYLWURDQGWKHXSUHJXODWLRQRI&FOLQWKH
FRORQLF WLVVXH RI WHWUDF\FOLQHWUHDWHG FROLWLFPLFHZH SURSRVHG WKDW D SRWHQWLDWLRQ RI WKH0ĭ
UHVSRQVHPLJKWXQGHUOD\WKHLUDQWLLQIODPPDWRU\HIIHFW$OWKRXJKVXVWDLQDEO\HOHYDWHGF\WRNLQH
OHYHOVPD\SHUSHWXDWH WKH LQIODPPDWRU\SURFHVVDQDGHTXDWH LQLWLDO LQIODPPDWRU\ UHVSRQVH LV
UHTXLUHGIRUDQHIIHFWLYHUHFRYHU\,QIDFW*:$6KDYHVKRZQWKDWDQLPPXQHGHILFLWXQGHUOLHV
WKH SDWKRJHQHVLV RI ,QIODPPDWRU\ %RZHO 'LVHDVH ,%'/HHV HW DO  FKDUDFWHULVHG E\
GLPLQLVKHG F\WRNLQH SURGXFWLRQ E\ PRQRF\WHV DQG DQ LPSDLUHG DELOLW\ RI WKH LQIODPPDWRU\
UHVSRQVH WR UHVWRUH LQWHVWLQDO KRPHRVWDVLV DV UHSRUWHG LQ &URKQ¶V 'LVHDVH SDWLHQWV 0DUNV
2I QRWH LPPXQRPRGXODWRU\ WHWUDF\FOLQHVSRWHQWLDWHG LQQDWH F\WRNLQH UHOHDVH E\ /36






WKH HQKDQFHG OHYHOV RI WKH DIRUHPHQWLRQHG F\WRNLQHV LQ01&WUHDWHGPLFH WKH LQLWLDO HYHQWV
PHGLDWLQJ LWVDQWLLQIODPPDWRU\ HIIHFWVPD\ LQFOXGH WKHSURPRWLRQRI0ĭ UHVSRQVH DQG WKHLU
FURVVWDON ZLWK ,/&V 6\VWHPLFDOO\ ZH REVHUYHG KLJKHU QXPEHUV RI FLUFXODWLQJP\HORLG FHOOV
DIWHU  GD\V RI 01& WUHDWPHQW OLQNLQJ ZLWK KLJKHU OHYHOV RI *0&6) ,/ DQG ,/ȕ
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SURWHFWLRQ DQG RSSRVH WR WKH GHWULPHQWDO LPPXQH UHVSRQVHREVHUYHG LQ FKURQLF LQIODPPDWRU\
GLVRUGHUV
7KH SURWHFWLYH FRQVHTXHQFHV RI WKHVH LPPXQH FKDQJHV DUH UHIOHFWHG LQ WKH HIIHFWV
HYLGHQFHGIRUWHWUDF\FOLQHVDWODWHUWLPHSRLQWVVXFKDVWKHLQFUHDVHLQPL57IIDQG7OU
H[SUHVVLRQUHFRYHUHGJREOHWFHOOIXQFWLRQDQGLPSURYHGHSLWHOLDOEDUULHULQWHJULW\%LWRQHWDO
 6XEVHTXHQW WR &FO DQG &FO XSUHJXODWLRQ HRVLQRSKLOV PDFURSKDJHV DQG '&V
DFFXPXODWHG LQ WKH F/3 RI 01&WUHDWHG PLFH (RVLQRSKLO DFWLYLW\ DWWHQXDWHV H[SHULPHQWDO
FROLWLV0DVWHUVRQHWDODQGLQFUHDVHGHRVLQRSKLOVKDYHEHHQIRXQGGXULQJWKHUHPLVVLRQ
SKDVH RI XOFHUDWLYH FROLWLV /DPSLQHQ HW DO  01& WUHDWPHQW SURPRWHG PRQRF\WH
UHFUXLWPHQW EXW DOVR WKHLU GLIIHUHQWLDWLRQ LQWR /\&0+&,, 0ĳV GHVSLWH WKH VXUURXQGLQJ
LQIODPPDWRU\ FRQGLWLRQV *0&6) ,/ DQG ,/ KDYH EHHQ GHVFULEHG WR SURPRWH WKH
SRODUL]DWLRQ RI LQIODPPDWRU\ 0ĭV WRZDUGV WKH KRPHRVWDWLF DQG DOWHUQDWLYHO\ DFWLYDWHG 0ĳ
SKHQRW\SHVLPSOLFDWHGLQEDFWHULDODQGDSRSWRWLFFHOOFOHDUDQFHDQGVXSSRUWLQJORFDOUHJXODWRU\
UHVSRQVHV DQG PXFRVDO KHDOLQJ +XQWHU HW DO  %DLQ HW DO   6LPLODUO\ 01&
SURPRWHG'&VUHFUXLWPHQWDQGWKHLQFUHDVHLQPLJUDWRU\'&V&'E&'FRUUHODWHGZLWK
DQ LQFUHDVH LQ&'7FHOOSULPLQJ LQ WKLVJURXS3DUWLFXODUO\KLJKHUQXPEHUVRI7UHJV7K
DQG7KVXEVHWVZHUHSUHVHQW LQ F/3RI01&WUHDWHGPLFH$OWKRXJK7KFHOOVKDYH LQLWLDO
SURWHFWLYH IXQFWLRQV LQ LQWHVWLQDO LQIODPPDWLRQ H[DFHUEDWHG 7K UHVSRQVHV FDQ OHDG WR
SHUSHWXDWHG LQIODPPDWLRQ DQG WLVVXH GDPDJH 2I QRWH 7K FHOOV FDQ GLIIHUHQWLDWH LQWR 7UHJ
FHOOVGXULQJWKHUHVROXWLRQRILQIODPPDWLRQ*DJOLDQLHWDODVZHOODVLQWRWKH7KVXEVHW
LQ UHVSRQVH WR ,/ /HH HW DO  DQG 01& WUHDWPHQW SURPRWHG D KLJKHU GHJUHH RI
SODVWLFLW\DPRQJWKHVH7FHOOVXEVHWVSDUWLFXODUO\EHWZHHQ7KDQG7K$GGLWLRQDOO\&&/
HQKDQFHV ,/ VHFUHWLRQ E\ 7 FHOOV DQG HOLFLWV 7K SRODULVLQJ HIIHFWV DQG PL5 KDV DQ
LPSRUWDQWUROHLQ'&SULPLQJRI7KUHVSRQVHV*XHWDO%HO]ERWKXSUHJXODWHG
LQ01&WUHDWHGPLFH
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XVHG WR VNHZPXFRVDO LPPXQH UHVSRQVHV DQG IDYRXU EDUULHU SURWHFWLRQ LQYROYH DOWHUQDWLYHO\
DFWLYDWHGPDFURSKDJHVHRVLQRSKLOV7KFHOOVDQG7UHJV6PLWKHWDO+XQWHUHWDO
*DXVHHWDO'ULVVHWDO7KHVHFHOOVSOD\DNH\UROHLQWKHUHVROXWLRQRILQWHVWLQDO
LQIODPPDWLRQ IRU H[DPSOH E\ SURGXFLQJ DQWLLQIODPPDWRU\ OLSLGPHGLDWRUV WKDW DFWLYDWH WKLV
SURFHVV6KHUPDQDQG.DOPDQ:DQJDQG&ROJDQ&RUUHODWLQJZLWKWKHVHLPPXQH
FKDQJHV$OR[ZDVXSUHJXODWHG LQ WKH01& WUHDWHGJURXSVXJJHVWLQJ WKH LQLWLDWLRQRI WKH
UHVROXWLRQSKDVH,QIDFWDWWKLVWLPHSRLQWFRORQLF,/DQG,/ȕOHYHOVGURSSHGWKHQXPEHU




7KH EHQHILWV RI ';& DQG 01& SUHYLRXVO\ UHSRUWHG LQ H[SHULPHQWDO FROLWLV +XDQJ HW DO
E*DUULGR0HVD HW DO D E  DQG LQ DPRGHO RI )8 LQGXFHG LQWHVWLQDO






DWDVSHFLILF WDUJHW KDYH DVSHFLDO LQWHUHVW LQ3KDUPDFRORJ\GXH WR WKH UDWLRQDOH WR DYRLGVLGH
HIIHFWV WKHUH LV LQFUHDVLQJDZDUHQHVVRI WKHLU ODFNRIHIILFDF\ LQFRPSOH[SDWKRORJLHVVXFKDV
,%'GXHWRFRXQWHUUHJXODWRU\SDWKZD\VWKDWVXVWDLQLQIODPPDWLRQ%LDQFKHULHWDO%\
FRQWUDVW WKHKLJK WKHUDSHXWLFEHQHILWREVHUYHGZLWK WHWUDF\FLQHV LQSUHFOLQLFDOPRGHOVRI ,%'
DQG RWKHU PXOWLIDFWRULDO GLVHDVHV PLJKW EH SUHFLVHO\ UHODWHG WR WKHLU SOHLRWURSLF SURSHUWLHV
LQIOXHQFLQJ GLIIHUHQW IDFWRUV LQYROYHG LQ WKH LQIODPPDWRU\ UHVSRQVH *ULIILQ HW DO 
*DUULGR0HVD HW DO D7KHEHQHILW RI WKHLUQRQDQWLELRWLFSURSHUWLHVKDVDOUHDG\SURYHG
FOLQLFDO UHOHYDQFHVR LW LV UHDVRQDEOH WREHOLHYH WKDW WHWUDF\FOLQHVFDQEH UHSXUSRVHG IRURWKHU
QRQLQIHFWLRXV SDWKRORJLHV LQ WKH IXWXUH DQGZH KRSH WKLV UHSRUW ZLOO FRQWULEXWH WR GUDZ WKH
DWWHQWLRQ RYHU WKHVH LQWHUHVWLQJ GUXJV 7KLV WRJHWKHUZLWK WKHLU ZHOO NQRZQ DQGVDIH SURILOH
PDNHV WKHP YHU\ SURPLVLQJ FDQGLGDWHV IRU IXWXUH WUDQVODWLRQDO VWXGLHV LQWR KXPDQ GLVHDVH
6LPLODUO\ IXUWKHU UHVHDUFK LQWR PXOWLWDUJHW GUXJV DQG ZD\V RI H[SORLWLQJ SURUHVROYLQJ




Page 18 of 49
British Pharmacological Society






WKHGLVHDVH:HSUHYLRXVO\ UHSRUWHG WKDWZKHQ WDNHQ LQDSUHYHQWDWLYHPDQQHUQRVLJQLILFDQW
GLIIHUHQFHVZHUHREVHUYHGVXJJHVWLQJWKDWWKHPRGLILFDWLRQRIWKHPLFURELRWDLQWKLVFDVHKDGQR
GHOHWHULRXV HIIHFWV QHLWKHU EHQHILFLDO *DUULGR0HVD HW DO D 2Q WKLV JURXQG KHUH ZH
SURSRVHG D FXUDWLYH WUHDWPHQW RQFH LQIODPPDWLRQ LV HVWDEOLVKHG %XW FRQVLGHULQJ RXU QHZ
ILQGLQJV LQGLFDWLQJ WKDW WKH PLFURELRWD FRPSRVLWLRQ ZDV QRW UHVWRUHG LQ DQWLELRWLFWUHDWHG
JURXSVDQG WKH ULVNVRIG\VELRVLVDVVRFLDWHGZLWKDQWLELRWLF LQWDNHHJ OHDGLQJ WR&GLIILFLOH
LQIHFWLRQ 2ZHQV HW DO  WKH ORQJWHUP DGPLQLVWUDWLRQ RI WHWUDF\FOLQHV LQ WKLV FRQWH[W
PLJKWVHHPGLVFRXUDJHGDVZHOO2IQRWHHYHQ WKRXJK WKHLUXVHKDVQRWEHHQ DVVRFLDWHGZLWK
LQFUHDVHG& GLIILFLOH LQIHFWLRQ ZKHQ FRPSDUHG WR RWKHU DQWLELRWLFV 'HVKSDQGH HW DO 
:LWK WKLV LQ PLQG WKH UHFHQWO\ GHYHORSHG FKHPLFDOO\PRGLILHG WHWUDF\FOLQHV GHYRLG RI
DQWLELRWLF DFWLYLW\ RIIHU D SURPLVLQJ WRRO WR H[SORUH WKH SRWHQWLDO RI WKH LPPXQRPRGXODWRU\
SURSHUWLHV RI WHWUDF\FOLQHV DOORZLQJ  IRU ORQJWHUP WKHUDS\ LI QHHGHG /RNHVKZDU 
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LPPXQRPRGXODWRU\ WHWUDF\FOLQHV EHFRPH D SURPLVLQJ VWUDWHJ\ IRU WKH WUHDWPHQW RI DFXWH
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PRGLI\LQJ WKHFRXUVHRI WKHGLVHDVH DQG ,%'SDWLHQWVZLWKRXWD UREXVWPXFRVDOKHDOLQJKDYH
ZRUVH RXWFRPHV %DHUW HW DO  7KXV E\ VWULNLQJ DW WKH LPPXQH V\VWHP FXUUHQW
SKDUPDFRORJLFDOWUHDWPHQWVPD\LQWHUIHUHZLWKWKHQDWXUDOSURWHFWLYHSDWKZD\VDFWLYDWHGE\WKH
LQIODPPDWRU\UHVSRQVH:HKDYHQRZJHQHUDWHGVROLGHYLGHQFHRIWKHEHQHILWRIVWUHQJWKHQLQJ
WKHVHGHIHQVLYHPHFKDQLVPVZLWK WKHDGPLQLVWUDWLRQRI LPPXQRPRGXODWRU\ WHWUDF\FOLQHV7KLV
DGGVWRWKHEURDGUDQJHRISURPLVLQJSURSHUWLHVH[HUWHGE\WKLVVDIHDQGZHOONQRZQIDPLO\RI
FRPSRXQGV RIIHULQJ DQ DSSHDOLQJ GUXJUHSRVLWLRQVWUDWHJ\ WRPDQDJH LQWHVWLQDO LQIODPPDWRU\
FRQGLWLRQV 
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Figure 1: Comparative study of the effects of rifaximin (RFX), tetracycline (TTC), doxycycline (DXC), 
minocycline (MNC), tigecycline (TGC) and dexamethasone (DEX) on MΦ activity in vitro. A) Nitrite 
production by LPS,stimulated RAW 264 MΦs. Cells were incubated with the different treatments at the 
indicated concentrations for 24h and then stimulated with LPS (100 ng/ml) for 24h. Nitrite concentration in 
the culture supernatant was measured by the Griess Assay. Data is expressed as mean ± SEM (n=6). B) 
Inos mRNA expression quantified by real,time PCR and C,E)  Cytokine concentration in the culture 
supernatant quantified by ELISA, in LPS,stimulated (10 ng/ml) BMDM after 24h of pre,incubation with the 
different treatments (25µM). Data expressed as mean ± SEM (n=6). Fold increase is calculated vs. 
unstimulated untreated cells. *P<0.05 vs. stimulated untreated cells.  
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Figure 6: Evaluation of the effects of 2 days of minocycline treatment on the immune response in DSScolitic 
mice. NC: Noncolitic group, DSS: DSScolitic group, MNC: minocyclinetreated colitic group. A) % of the 
indicated immune cell populations in the blood of the different experimental groups. B) Analysis of immune 
cell populations in the cLP of the different experimental groups. Absolute cell numbers of B cells (B220+), 
CD4+T cells (CD3+), Tregs (CD3+CD4+FoxP3+), neutrophils (Ly6G+) and Ly6C+MHCII Mφs. Scatter plots 
represent individual values (dots) and mean ± SEM. C) colon mRNA expression quantified by realtime PCR. 
Fold increase calculated vs. NC group. D) Cytokine concentration in the supernatant of colonic explant 
cultures quantified by ELISA.  Boxes graph represents ±SEM range, median (middle line) and extreme 
values (whiskers) (n=5). *P<0.05 vs. DSS control group, #P>0.05 vs NC control group.  
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Figure 8: Evaluation of the effects of 4 days of minocycline treatment on the cLP immune response during 
DSS colitis. NC: Non!colitic group, DSS: DSS!colitic group, MNC: minocycline!treated colitic group (50 
mg/kg/d) (n=7, DSS n=6). A) Representative flow cytometry analysis of live cells from the cLP showing the 
CD11b+ and CD45+ cell populations. B) Absolute cell numbers of immune cells (CD45+) and 
CD45+CD11b+ myeloid cells. C) Representative flow cytometry analysis of CD11b+ cells from the cLP 
showing the Ly6G+ and SiglecF+ populations. D) Absolute cell numbers of: neutrophils (Ly6G+), eosinophils 
(SiglecF+) and myeloid monocytic cells (CD11b+ Ly6G! SiglecF! SSClo). E) Total number of MΦs 
(CD11b+Ly6G!SSCloF4/80+ cells) F) Representative flow cytometry plots showing showing the expression 
of Ly6G and MHCII by MΦs from the cLP and illustrating the monocyte!MΦ waterfall. G) Percentage (left) 
and absolute cell numbers (right) of: Inflammatory MΦs (Ly6C+MHCII! cells), Intermediate MΦ population 
(Ly6C+MHCII+ cells) and Resident intestinal MΦs (Ly6C!MHCII+ cells). H) Absolute cell numbers of DCs 
(Ly6G!SSCloF4/80!CD11chiMHCII+) and percentage of CD11b+CD103+ DCs. I) Representative flow 
cytometry analysis of DCs from the cLP showing the expression of CD103 and CD11b. Scatter plots 
represent individual values (dots) and mean ± SEM. *P<0.05 vs. DSS control group, #P>0.05 vs NC control 
group.  
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Dear Dr Garrido Mesa, 
 
 
Re 2018-BJP-0110-RP.R1: "Immunomodulatory tetracyclines shape the intestinal 
inflammatory response inducing mucosal healing and resolution." 
 
Your revised paper has been seen by an editor and expert referees. I enclose below the 
comments received that set out a number of additional points which will need your 
attention before we can consider the submission further. I would urge you to give 
these points your careful attention. 
 
I hope that you will be prepared to make the necessary amendments and submit a 
revised manuscript within three months. This should be accompanied by a statement 
of how you have responded to the criticisms raised, preferably numbered point by 
point. Should you decide that you do not wish to submit a revised manuscript to BJP, 
please contact the Editorial Office so we may withdraw your manuscript from the 
system. 
 
Please highlight the changes to your manuscript within the document by using the 
track changes mode in MS Word or by using bold or colored text. Please read the 
author instructions carefully prior to re-submission. 
 
Please DO NOT upload your revised manuscript as a new submission. To revise your 
submitted manuscript, log into https://mc.manuscriptcentral.com/bjp and enter your 
Author Centre, where you will find your manuscript title listed under "Manuscripts 
with Decisions."  Under "Actions" click on "Create a Revision".  Your manuscript 
number will be appended to denote the revision. 
 
Although the journal is online-only, authors will still be able to order reprints of their 
own articles. To order reprints, please use the following email 
address: offprint@cosprinters.com. You should supply the journal and article title 
name, preferably with a URL link to the published manuscript. 
 
Colour in the British Journal of Pharmacology is free; where appropriate, please 
consider submitting your figures in colour. You can also refer to 
 
 





Dr Mark Giembycz 
 
Senior Editor, British Journal of Pharmacology 
giembycz@ucalgary.ca 
 
Page 43 of 49
British Pharmacological Society




The sample sizes in Table 4 must be at least N = 5. Please revise. 
The authors must also provide clinical significance for their findings as suggested by 
reviewer 3. 
The role of gut microbiota that is also raised by reviewer 3 must be addressed. 
 
Comments to the Author 
One of the referees has serious doubts about the clinical significance of the study. 
Please address this issue in any revision. 
 
 
Dear Dr. Giembycz 
 
The data presented in table 4 was obtained in the same pyrosequencing analysis as 
the results showed in Figure 5. As we mentioned in more detail in our previous 
response to reviewers comments concerning sample size: Due to technical problems 
(no amplification in some samples) and loss of sample recovery, particularly in the 
groups with lower or no therapeutic effect (owing to the diarrheic process), we could 
only reach n=4. Therefore, beside the most relevant groups of the study have an n≥5 
(untreated controls and the tree groups treated with immunomodulatory 
tetracyclines), to comply with the guidance of BJP, the statistical analysis is not 
shown for the microbial data (figure 4 and 5). This was mentioned in the text (lines 
232-235). We apologise for the reduced N in these groups, but even though we tried 
to sequence again some of the samples that did not amplify, we got the same lack of 
result. Please also consider the fact that many researchers find the same difficulties 
and have to report reduced sample size in these studies (Yuksel et al., 2015; Kim et 
al., 2017; Shin et al., 2017).  
  
Please find bellow our response to the concerns raised by reviewer 3 concerning the 
clinical relevance of the study and the role of intestinal microbiota. Some of these 
questions were already answered in the response to reviewers 1 and 2, and 
modifications were already included in the previous version of the manuscript 
regarding these topics (red coloured text). We have now included additional changes 
in the manuscript in order to emphasize the clinical relevance of our findings and set 
the microbial studies in the context of the role of the microbiota in these conditions 
(new modifications highlighted in yellow). However, despite the interesting role of 
dysbiosis and antibiotics in the aethiology of IBD (well known), antibiotics have been 
long used, and they are still used, to treat IBD without published record of a negative 
impact on the course of the disease. On this ground, here we proposed a curative 
treatment (once disease is established) and our results indicate that the impact of 
tetracyclines on the microbiota does not have a major contribution to their effect, 
whereas the novel immunomodulatory mechanism described here does it. 
Therefore, while we have extensively answered below to reviewer 3, we believe that 
these novel findings should be the focus of the discussion and the manuscript. May 
you consider appropriate to include any additional comment, please let us know and 
we will undertake the suggested amendments.   
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Reviewers' Comments to Author: 
Reviewer: 2 
Comments to the Author 
Dear Authors, 
The revised manuscript represents the contents and the discussion points well. The 
point-to-point response to the reviewers' comments are concise and clear. 
 
Reviewer: 3 
Comments to the Author 
This manuscript is of good quality, well written and I have no specific complaints on 
the methodology. However, one limitation of the scientific proposal is the lack of a 
clinical view of this approach. There is no mention about the impact of tetracycline 
treatment on gut microbiota. The microbiota is one of the most important regulators 
of gut homeostasis, and its alteration has been linked to IBD triggering and 
perpetuation in humans. The immunomodulatory effect of tetracycline (already 
known) appears very limited without a look at what happens on microbiota today. It is 
a good manuscript, but lacking of a more modern view of IBD treatments, and in this 
form remains a an end in itself. 
 
We completely agree with the reviewer about the relevance of the microbiota in 
intestinal inflammatory conditions. This was indeed one of the reasons why we 
performed a comparative study including different antibiotics (figures 2-5). We did 
not only evaluate their intestinal anti-inflammatory effect here, but we specifically 
assessed the impact of the treatments in the microbiota composition (shown in table 
4 and figure 5). These studies showed that the impact exerted on the microbiota 
composition by all the antibiotics tested was very similar, while only those with 
immunomodulatory properties ameliorated the inflammatory response, suggesting 
that the immunomodulatory effect is significantly more relevant than the antibiotic 
one. Therefore, this study encourages and provides the scientific support for the 
development and evaluation of tetracycline-based molecules, devoid of antibiotic 
properties but retaining the immunomodulatory potential leading to the activity 
described here for the first time. This was discussed in lines 404-407, 478-481, 508-
517 and 529-535 of the manuscript (new modifications highlighted in yellow, 
previous modifications in red text) 
 
We are well aware of the epidemiological reports that associated antibiotic intake 
and IBD development, i.e. (Shaw et al., 2011; Ungaro et al., 2014). But as the most 
recent studies have determined, the disruption cause by antibiotics leading to IBD is 
particularly relevant earlier in life (Miyoshi et al., 2017; Aniwan et al., 2018; Örtqvist 
et al., 2018), not as an immediate trigger. This indicates that the cause-effect 
relationship is not only the microbial dysbiosis, but also the impact on the 
development of the immune system (Schulfer et al., 2018). But it is obvious that 
antibiotics play a role, we are not denying that, and we do find this field interesting 
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and relevant for consideration. However, this association does not apply to our study 
and the proposed clinical applications for several reasons:   
1) We are not suggesting the use of antibiotics in patients without IBD or even 
as a preventive treatment in IBD patients before the development of an 
inflammatory flare, but as a curative short-term treatment. This is also based 
on a previous report describing that, when taken in a preventative manner, 
no significant differences were observed in between untreated and 
minocycline-treated mice, suggesting that the modification of the microbiota 
in this case had no deleterious effects, neither beneficial (Garrido-Mesa et al., 
2011a).  
2) For the application suggested here, it is interesting to note the lack of reports 
describing that antibiotic intake by IBD patients is linked to a perpetuation of 
the disease (we couldn’t find any at least). Considering the availability of 
studies describing the role of antibiotics in the aetiology of IBD (some 
referenced above) but the lack of the others, it seems that once the 
pathology/susceptibility has been developed, microbial disruption by 
antibiotics may not have such an important impact. Indeed, antibiotics have 
been long used in IBD, so it is likely that a deterioration of the pathology 
would have already been described. So clinicians still consider antibiotics 
among the therapeutic arsenal for IBD and there are even clinical trials 





=doxycycline+AND+Antibiotics&rank=3. Therefore, antibiotics are used by 
clinitians despite the aetiological association and, on this ground, 
immunomodulatory tetracyclines could provide a therapeutic advantage over 
other antibiotics. As a short-term treatment (3-7 days), these drugs could 
push the on-going inflammation down a resolution pathway that could be 
maintained with “microbiota-friendly” drugs such as probiotics, a therapeutic 
combination that we previously reported to be effective in relapsing 
experimental colitis (Garrido-Mesa et al., 2011b, 2015). Also take in 
consideration that the potential benefit of the activity described here should 
not only be limited to IBD, but also to other intestinal inflammatory 
conditions. 
3) Having said that, we do share the reviewers concern about the adverse 
effects of the antibiotic action of tetracyclines, even when given 
therapeutically and not for a long-period. But no drug is devoid of adverse 
effects, so this should not be a limitation for its evaluation, but further 
encourage studies in order to improve it. Especially when the therapeutic 
option has proved added interest, as this and previous reports do. Following 
on from the results obtained here (it is not our intention for this report to 
remain as an end in itself), we have initiated the evaluation of one 
chemically-modified tetracycline provided by Galderma, which we hope will 
retain the anti-inflammatory mechanisms described here without the 
disadvantage of the antibiotic activity. These compounds are currently being 
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evaluated in clinical trials for their potential to inhibit metastasis. 
Additionally, we have also initiated studies to determine the functional role 
of the microbiota changes observed here. We have started with faecal 
transference experiments, giving microbiota derived from NC, DSS and MNC 
groups (similar setting used in this study) to recipient mice and evaluating the 
differential susceptibility to DSS colitis. We observed that mice receiving 
microbiota derived from NC and MNC groups showed slightly reduced 
susceptibility than the mice receiving DSS faecal contents. These results are 
too preliminary and we need to further characterised and confirm these 
results, but it is at least encouraging since we did not observed a negative 
impact.   
          
Page 47 of 49
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
 
We have further discussed the impact of the microbiota and the possible 
implications in the revised version of the manuscript (lines 136-139 and 500-507, in 
addition to previously related comments in lines 404-407, 478-481, 508-517 and 529-
535), but please note that these are not the most interesting results of the study and, 
therefore, should not be the focus of the manuscript.  
 
Regarding the clinical relevance, it is evident that our studies are preclinical, and the 
relevance and clinical significance of these findings will have to be assessed in the 
appropriate clinical studies. However, from a pharmacological point of view, we 
believe that the results of our study, and the potential of the novel mechanism 
described here, encourage to continue with this line of research. Although the 
presence of immunomodulatory effects on tetracyclines has previously been 
reported, their ability to potentiate a protective innate response has never been 
described before until now. Indeed, our findings align with the more modern view of 
IBD pathology: considering how our understanding has evolved in recent years, and 
the key role that we now know defects in innate immunity and mucosal barrier play 
in IBD pathogenesis, the development and study of new therapeutic approaches that 
aim at restoring these protective mechanisms is the next logical approach in IBD.  
As commented in the manuscript, the fact that these drugs are already approved and 
have been safely used in clinical practice for over 40 years is of key relevance for any 
human translational studies. It is also relevant to mention their evaluation and used 
in non-infectious pathologies (Garrido-Mesa et al., 2013) and, in fact, there are 
numerous clinical trials testing these drugs (255 for minocycline, 295 for doxycycline 
and 68 for tigecycline), not only in infectious conditions (https://clinicaltrials.gov/). 
Having these antibiotics proved clinical relevance besides their antibiotic properties 
previously, it is reasonable to believe they can also be repurposed for other 
pathologies in the future, and we hope this report will contribute to draw the 
attention of clinicians and pharmaceutical companies into the potential of the 
mechanism described here. Unfortunately, it is not in our hands to initiate the 
required clinical trials, but to provide scientific base for others to carry on with this 
therapeutic opportunity. 
We have modified the manuscript to include some the comments mentioned above 
to emphasise the clinical relevance of our findings and to show how this therapeutic 
option could impact IBD therapy (new modifications included in lines 492-495 and 
527-529, in addition to previously related comments in lines 35-36, 71-77, 399-404, 
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